A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Repeated Intra-Articular Injection of SI-613 in Patients With Osteoarthritis of the Knee
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs SI 613 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Seikagaku Corporation
- 26 Sep 2017 Planned End Date changed from 1 Jul 2018 to 1 Nov 2018.
- 26 Sep 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018.
- 21 Jun 2017 New trial record